メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
富山大学 ホーム
日本語
English
ホーム
プロファイル
研究部門
プロジェクト
研究成果
データセット
受賞
活動
コース
専門知識、名前、または所属機関で検索
外科学(消化器・腫瘍・総合外科)講座
富山大学
医学系
概要
フィンガープリント
ネットワーク
プロファイル
(13)
プロジェクト
(14)
研究成果
(322)
データセット
(6)
フィンガープリント
外科学(消化器・腫瘍・総合外科)講座が活動している研究トピックを掘り下げます。これらのトピックラベルは、この組織のメンバーの研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Medicine and Dentistry
Abdominal Cancer
54%
Adenocarcinoma
13%
Adjuvant Chemotherapy
15%
Adverse Event
5%
Artery
9%
Biological Marker
11%
Bleeding
15%
Body Mass Index
5%
Breast Cancer
7%
C Reactive Protein
6%
Cancer
14%
Cancer Cell
17%
Cancer Surgery
6%
Carcinoma
10%
Chemoradiotherapy
9%
Chemotherapy
26%
Cholangiocarcinoma
13%
Colorectal Carcinoma
11%
Colorectal Liver Metastasis
6%
Computer Assisted Tomography
18%
Cytotechnology
9%
Diagnosis
7%
Disease
13%
Disease Free Survival
12%
Distal Pancreatectomy
23%
Duodenum
5%
Elderly Patient
6%
Embolization
6%
Esophageal Cancer
12%
Esophageal Squamous Cell Carcinoma
21%
Esophagectomy
21%
Esophagus
16%
Fluorodeoxyglucose
7%
Gastrectomy
19%
Gemcitabine
15%
Hazard Ratio
11%
Head Cancer
7%
Hepatectomy
53%
Hepatic Portal Vein
24%
Hepatocellular Carcinoma
63%
Indocyanine Green
6%
Intraductal Papillary Mucinous Tumor
15%
Jejunum
6%
Laparoscopic Surgery
7%
Liver Metastasis
20%
Long Term Survival
7%
Lymph Node
12%
Lymph Node Metastasis
20%
Lymphocyte
15%
Magnetic Resonance Imaging
7%
Malignant Neoplasm
39%
Median Survival Time
7%
Melanoma Antigen
7%
Mesenchymal-Epithelial Transition
7%
Messenger RNA
18%
Metastatic Carcinoma
27%
Methylation
6%
Multivariate Analysis
22%
Neoadjuvant Therapy
7%
Neoplasm
86%
Neutrophil
6%
Nutrition Assessment
7%
Odds Ratio
10%
Operation Duration
7%
Overall Survival
37%
Paclitaxel
9%
Pancreas Adenocarcinoma
32%
Pancreas Cancer
100%
Pancreas Carcinoma
5%
Pancreas Fistula
23%
Pancreas Islet Cell Tumor
7%
Pancreatectomy
23%
Pancreatic Duct
7%
Pancreatic Surgery
11%
Pancreaticoduodenectomy
50%
Pancreaticojejunostomy
6%
Peritoneum Metastasis
14%
Platelet
8%
Positron Emission Tomography
6%
Postoperative Complication
13%
Predictive Factor
8%
Prognostic Factor
30%
Randomized Controlled Trial
7%
Recurrence Free Survival
13%
Recurrent Disease
50%
Retroperitoneal Lymph Node Dissection
10%
Retrospective Study
7%
Skeletal Muscle
8%
Splenic Vein
8%
Squamous Cell Carcinoma
6%
Stenosis
6%
Superior Mesenteric Artery
6%
Surgery
82%
Surgical Anastomosis
11%
Survival Rate
11%
Tail
11%
Tumor Marker
6%
Tumor Progression
7%
Ulcerative Colitis
8%
Univariate Analysis
8%
Keyphrases
Adjuvant Chemotherapy
12%
Advanced Gastric Cancer
8%
After Surgery
12%
Antitumor Effect
7%
Array Analysis
9%
Bevacizumab
8%
Cancer Patients
7%
Chemotherapy
18%
Cluster of Differentiation 44 (CD44)
7%
Colorectal Cancer
12%
Colorectal Liver Metastases
13%
Computed Tomography
14%
Confidence Interval
13%
Conversion Surgery
7%
Curative Resection
16%
Disease-free Survival
14%
Distal Pancreatectomy
16%
Epithelial-to-mesenchymal Transition
10%
Esophageal Cancer
10%
Esophageal Squamous Cell Carcinoma
31%
Expression Level
9%
Gastric Cancer
56%
Gastric Cancer Cell Lines
8%
Gastric Cancer Cells
7%
Gastric Tissue
8%
Gemcitabine
14%
Gemcitabine Plus Nab-paclitaxel
8%
Hazard Ratio
12%
Hepatectomy
14%
Hepatic Metastasis
8%
Hepatic Resection
24%
Hepatocellular Carcinoma
88%
Hepatocellular Carcinoma Cells
8%
In Cancer
7%
Independent Prognostic Factor
16%
Intraductal Papillary mucinous Neoplasm
16%
Japan
17%
Japan Pancreas Society
7%
Liver
13%
Liver Metastasis
10%
Long-term Survival
9%
Lymph Node Metastasis
16%
Malignancy
7%
Malignant Phenotype
12%
Median Survival Time
7%
Metastasis
10%
Metastatic Colorectal Cancer (mCRC)
7%
Multivariate Analysis
22%
Neoadjuvant Chemoradiotherapy (nCRT)
7%
Neoadjuvant Therapy
7%
No Significant Difference
7%
Odds Ratio
11%
Older Men
14%
Older Women
10%
Oncolytic Herpes Simplex Virus (oHSV)
10%
Overall Survival
34%
Overexpression
9%
Pancreas
18%
Pancreatectomy
19%
Pancreatic Cancer
84%
Pancreatic Ductal Adenocarcinoma
26%
Pancreatic Fistula
12%
Pancreatic Head
7%
Pancreatic Head Cancer
7%
Pancreatic Resection
7%
Pancreatic Surgery
7%
Pancreaticoduodenectomy
49%
Pathological Findings
8%
Patient Survival
7%
Peritoneal Cytology
7%
Peritoneal Dissemination
8%
Peritoneal Metastasis
18%
Phase II Study
9%
Poor Prognosis
17%
Portal Vein
10%
Postoperative Complications
13%
Postoperative Day
12%
Postoperative Outcomes
7%
Postoperative Pancreatic Fistula
13%
Postoperative Prognosis
7%
Prognosis Prediction
9%
Prognostic Factors
20%
Prognostic Impact
8%
Prognostic Significance
9%
Promoter Methylation
8%
Propensity Score Analysis
7%
Recurrence-free Survival
12%
Resectable Pancreatic Cancer
23%
Resection
26%
Risk Factors
11%
Splenic Vein
8%
Stomach
11%
Surgical Resection
6%
Triple Combination Array
8%
Tumor
49%
Tumor Size
7%
Tumor Suppressor
9%
Tumor Suppressor Gene
9%
Ulcerative Colitis
9%
Univariate Analysis
7%